Publications APREC / Années
Contenu
2013 2
2012 4
2011 6
2010 8
2009 10
2008 12
2007 15
2006 17
2005 19
2004 21
2003 23
2002 24
2001 25
2000 26
1999 27
1998 29
1997 31
1996 32
1995 34
1994 35
1993 36
1991 37
1990 38
ANNEE / NOMBRE D’ARTICLES2013 / 16
2012 / 19
2011 / 20
2010 / 17
2009 / 15
2008 / 29
2007 / 16
2006 / 24
2005 / 15
2004 / 21
2003 / 11
2002 / 8
2001 / 9
2000 / 9
1999 / 15
1998 / 15
1997 / 11
1996 / 19
1995 / 6
1994 / 3
1993 / 5
1991 / 2
1990 / 1
TOTAL / 306
2013
1- Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; Lotz JP; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol, 24(9):2342-9, 2013. doi: 10.1093/annonc/mdt231
2- Lévy P,Gligorov J, Antoine M, Rezai K, Lévy E, Selle F, Saintigny P, Lokiec F, Avenin D, Beerblock K, Lotz JP, Bernaudin JF, Fajac A. Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat, 139(2):421-8, 2013.doi: 10.1007/s10549-013-2545-7
3- Popovic L, Jovanovic D, Donat D, Petrovic D, Roganovic T, Lotz JP. High dose chemotherapy with autologous stem cell transplantation for patients with germ-cell cancer. J BUON, 18(1):290-1, 2013.
4- Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; Lotz JP; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol, 14(1):29-37, 2013. doi: 10.1016/S1470-2045(12)70477-1
5- Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germá Lluch JR, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LH, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol, 24(4):878-88, 2013. doi: 10.1093/annonc/mds579
6- Thariat J, Schouman T, Brouchet A, Sarini J, Miller RC, Reychler H, Ray-Coquard I, Italiano A, Verite C, Sohawon S, Bompas E, Dassonville O, Salas S, Aldabbagh K, Maingon P, de La MotteRouge T, Kurtz JE, Usseglio J, Kerbrat P, Raoul G, Lotz JP, Bar-Sela G, Brugières L, Chaigneau L, Saada E, Odin G, Marcy PY, Thyss A, Julieron M. Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE. Ann Oncol, 24(3):824-31, 2013. doi: 10.1093/annonc/mds507
7- Hurvitz SA, Dalenc F, Campone M, O'Regan RM, Tjan-Heijnen VC,Gligorov J, Llombart A, Jhangiani H, Mirshahidi HR, Tan-Chiu E, Miao S, El-Hashimy M, Lincy J, Taran T, Soria JC, Sahmoud T, André F. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat, 141(3):437-46, 2013. doi: 10.1007/s10549-013-2689-5
8- Pivot X,Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol, 14(10):962-70, 2013. doi: 10.1016/S1470-2045(13)70383-8
9- Séroussi B, Laouénan C,Gligorov J, Uzan S, Mentré F, Bouaud J. Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support? Br J Cancer, 109(5):1147-56, 2013. doi: 10.1038/bjc.2013.453
10- Robert T, Moktefi A, Wiig H, Brochériou I, Michaud L, Gligorov J, Finianos S, Hertig A. Acute kidney failure with renal carcinomatous lymphangitis secondary to advanced colon cancer. Kidney Int, 84(2):420, 2013. doi: 10.1038/ki.2012.480
11- Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; Gligorov J, Avenin D, PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol, 14(8):741-8, 2013. doi: 10.1016/S1470-2045(13)70225-0
12- Thibault C, Khodari W, Lequoy M,Gligorov J, Belkacémi Y. HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: a review. Crit Rev Oncol Hematol, 88(1):123-33, 2013. doi: 10.1016/j.critrevonc.2013.03.003
13- Lagha A, Chraiet N, Labidi S, Krimi S, Ayadi M, Gligorov J, Boussen H. [Impact of taxanes in the adjuvant setting of node-negative breast cancers]. Bull Cancer 100(5):465-71, 2013. doi: 10.1684/bdc.2013.1743
14- Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA, Kyriakides S, Pagani O, Senkus E, Costa A, Gligorov J, Winer EP; ESO-MBC Task Force. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast, 22(3):203-10, 2013. doi: 10.1016/j.breast.2013.03.006
15- Touboul C, Bezu C, Daraï E, Chopier J, Touboul E, Gligorov J, Rouzier R, Uzan S. [Are decisions of multidisciplinary tumor boards in accordance with the guidelines? Experience of an university reference center for breast cancer]. Gynecol Obstet Fertil, 41(3):164-7, 2013. doi: 10.1016/j.gyobfe.2013.01.003
16- Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F, Guillemet C, Weber B, Largillier R, Bertucci F, Opinel P, Duffaud F, Reynaud-Bougnoux A, Delcambre C, Isambert N, Kerbrat P, Netter-Pinon G, Pinto N, Duvillard P, Haie-Meder C, Lhommé C, Rey A. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol, 24(4):1099-104, 2013. doi: 10.1093/annonc/mds545
2012
1- Gerotziafas GT, Galea V, Mbemba E, Sassi M, Roman MP, Khaterchi A, van Dreden P, Japcowitz M, Lotz JP, Bernaudin JF, Fareed J, Hatmi M, Elalamy I. Effect of Low Molecular Weight Heparins and Fondaparinux upon Thrombin Generation Triggered by Human Pancreatic Cancer Cells BXPC3. Curr Vasc Pharmacol Jun 22, 2012.
2- Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ, Lotz JP; IES Steering Committee. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol 13(4):420-32, 2012. doi: 10.1016/S1470-2045(11)70328-X
3- Bui-Nguyen B, Ray-Coquard I, Chevreau C, Penel N, Bay JO, Coindre JM, Cupissol D, Italiano A, Bonichon F, Lotz JP, Thyss A, Jimenez M, Mathoulin-Pélissier S, Blay JY; GSF-GETO French Sarcoma Group. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Ann Oncol, 23(3):777-84, 2012. doi: 10.1093/annonc/mdr282
4- Belkacémi Y, Boussen H, Turkan S, Tsoutsou PG, Geara F,Gligorov J. Fight against cancer around the Mediterranean area: "Many hands make light work!" Crit Rev Oncol Hematol, 84 Suppl 1:e1-5, 2012. doi: 10.1016/j.critrevonc.2012.10.004
5- Vataire AL, Laas E, Aballéa S, Gligorov J, Rouzier R, Chéreau E. [Cost-effectiveness of a chemotherapy predictive test]. Bull Cancer, 99(10):907-14, 2012. doi: 10.1684/bdc.2012.1652
6- Joensuu H,Gligorov J. Adjuvant treatments for triple-negative breast cancers. Ann Oncol, 23 Suppl 6:vi40-5, 2012.
7- Laas E, Vataire AL, Aballea S, Valentine W, Gligorov J, Chereau E, Rouzier R. Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France. J Med Econ, 15(6):1167-75, 2012. doi: 10.3111/13696998.2012.713414
8- Chéreau E, Bezu C,Gligorov J, Sakr R, Antoine M, Daraï E, Uzan S, Rouzier R. Impact of immunohistochemical analysis of sentinel lymph node biopsy on breast cancer management. Anticancer Res, 32(8):3403-9, 2012.
9- Genin AS, Lesieur B,Gligorov J, Antoine M, Selleret L, Rouzier R. Pregnancy-associated breast cancers: do they differ from other breast cancers in young women? Breast, 21(4):550-5, 2012. doi: 10.1016/j.breast.2012.05.002
10- Martín M, Makhson A,Gligorov J, Lichinitser M, Lluch A, Semiglazov V, Scotto N, Mitchell L, Tjulandin S. Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. Oncologist, 17(4):469-75, 2012. doi: 10.1634/theoncologist.2011-0344
11- Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van't Veer L, Viale G, Krop I, Winer E. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast, 21(3):242-52, 2012. doi: 10.1016/j.breast.2012.03.003
12- Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard FC, Viens P. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol, 13(4):375-84, 2012. doi: 10.1016/S1470-2045(12)70049-9
13- Frati A, Chereau E, Coutant C, Bezu C, Antoine M, Chopier J, Daraï E, Uzan S, Gligorov J, Rouzier R. Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors. Breast Cancer Res Treat, 132(2):601-7, 2012. doi: 10.1007/s10549-011-1897-0
14- Gligorov J, Launay-Vacher V, Aapro M. [Treatments of metastases in cancer]. Bull Cancer, 1;99(3):333-43, 2012. doi: 10.1684/bdc.2011.1481
15- Beuzeboc P, Le Tourneau C, Gligorov J, Janus N, Spano JP, Ray-Coquard I, Deray G, Launay-Vacher V. [Renal insufficiency and breast cancer]. Bull Cancer, 99(3):309-15, 2012. doi: 10.1684/bdc.2011.1478.
16- Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ,Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G. Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast, 21(1):20-6, 2012. doi: 10.1016/j.breast.2011.09.006
17- Lheureux S, Krieger S, Weber B, Pautier P, Fabbro M, Selle F, Bourgeois H, Petit T, Lortholary A, Plantade A, Briand M, Leconte A, Richard N, Vilquin P, Clarisse B, Blanc-Fournier C, Joly F. Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial. Int J Gynecol Cancer, 22(9):1483-8, 2012. doi: 10.1097/IGC.0b013e31826d1438
18- Revaux A, Rouzier R, Ballester M, Selle F, Daraï E, Chéreau E. Comparison of morbidity and survival between primary and interval cytoreductive surgery in patients after modified posterior pelvic exenteration for advanced ovarian cancer. Int J Gynecol Cancer, 22(8):1349-54, 2012.
19- Chéreau E, Ballester M, Selle F, Rouzier R, Daraï E. [Clues for paraaortic lymphadenectomy in patients older than 70 years with ovarian cancer]. Gynecol Obstet Fertil, 40(5):327-9, 2012. doi: 10.1016/j.gyobfe.2012.02.018
2011
1- Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M, Stadtmauer EA, Biron P, Crown JP, Schmid P, Lotz JP, Rosti G, Bregni M, Demirer T. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol, 20;29(24):3224-31, 2011. doi: 10.1200/JCO.2010.32.5936
2- Coussy F, Chéreau E, Daraï E, Dhombres F, Lotz JP, Rouzier R, Selle F. [Interest of CA 125 level in management of ovarian cancer]. Gynecol Obstet Fertil, 39(5):296-301, 2011. doi: 10.1016/j.gyobfe.2010.10.018
3- Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin K, Lotz JP, Germà-Lluch JR, Powles T, Kollmannsberger C, Beyer J. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol, 29(16):2178-84, 2011. doi: 10.1200/JCO.2010.32.6678
4- Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J, Gligorov J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med, 365(14):1273-83, 2011. doi: 10.1056/NEJMoa0910383
5- Curtit E, Nouyrigat P, Dohollou N, Levy E, Lortholary A,Gligorov J, Facchini T, Jaubert D, Maille N, Pivot X, Grangé V, Cals L. Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. Eur J Cancer, 47(16):2396-402, 2011. doi: 10.1016/j.ejca.2011.08.004
6- Frati A, Antoine M, Rodenas A, Gligorov J, Rouzier R, Chéreau E. [Somatostatin in breast cancer]. Ann Biol Clin (Paris), 69(4):385-91, 2011. doi: 10.1684/abc.2011.0588
7- Decanter C, Gligorov J. [Oocyte/embryo cryopreservation before chemotherapy for breast cancer]. Gynecol Obstet Fertil, 39(9):501-3, 2011. doi: 10.1016/j.gyobfe.2011.07.011
8- Penault-Llorca F, Coeffic D, Delozier T, Dohollou N, Freyer G, Gligorov J, Hardy-Bessard AC, Jacot W, Misset JL, Nabholtz JM, Petit T, Spielmann M, Namer M. [Node negative breast cancer. Beyond international consensus: a pragmatic approach]. Bull Cancer, 98(7):807-25, 2011. doi: 10.1684/bdc.2011.1395